A potent combination to
help prevent recurrent stroke
AGGRENOX combines two proven medicines for preventing TIA/stroke: a low dose of aspirin and extended-release dipyridamole. Together in AGGRENOX, these ingredients are more effective than either ingredient alone. In fact, AGGRENOX is twice as good as aspirin at helping prevent recurrent TIA/Stroke.
If you have had a TIA or stroke and are being treated with aspirin or other therapy, you should know that AGGRENOX is specifically approved to help prevent stroke following TIA/stroke.
Preview the sections to the right
to learn more about AGGRENOX.
- How AGGRENOX works
-
A powerful combination.
Most strokes are caused when blood clots form and block a blood vessel in the brain. AGGRENOX:- Makes platelets in the blood less sticky so they don’t clump together and form blood clots
- Contains two proven antiplatelet medicines that work together
- Is more effective than either of these medicines by itself
- AGGRENOX Effectiveness
-
Twice as effective as aspirin.
AGGRENOX was proven effective in a large international stroke prevention trial — the Second European Stroke Prevention Study (ESPS 2). In the study, AGGRENOX:- Prevented twice as many strokes as aspirin, the most widely used stroke prevention treatment
- Reduced the risk of recurrent stroke in patients with heart disease and high blood pressure
- AGGRENOX Safety
-
The most common side effect is headache.
AGGRENOX is generally safe and well tolerated, and has been taken safely by hundreds of thousands of patients worldwide:- Headaches are usually mild and diminish over time
- AGGRENOX contains aspirin. Patients should avoid heavy alcohol use (3+ drinks a day) while taking aspirin
- GI bleeding with AGGRENOX was comparable to aspirin
- How to Take AGGRENOX
-
Taking AGGRENOX is easy.
More...
AGGRENOX should be taken twice a day — one capsule in the morning and another one in the evening.
If you can’t afford your AGGRENOX, our patient assistance program may be able to help.
Call 1 800 556 8317.
Important Information about AGGRENOX
AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.
In clinical trials, the most common adverse event with AGGRENOX was headache (38.2% vs 32.4% with placebo), which was more frequent at the onset of therapy but diminished over time. GI bleeding with AGGRENOX was comparable to aspirin (4.1% vs 3.2%) and intracranial hemorrhage with AGGRENOX was similar to placebo (0.6% vs 0.4%).
AGGRENOX contains aspirin. Patients who consume three or more alcoholic drinks every day should be counseled about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin. Even low doses of aspirin can increase bleeding time, which can adversely affect patients with bleeding disorders. Patients with a history of active peptic ulcer disease should avoid using aspirin, which can cause gastric mucosal irritation and bleeding. AGGRENOX should be avoided in the third trimester of pregnancy.
Click here for full AGGRENOX Prescribing Information.
Privacy Policy | Terms of Use | Contact Us | Sitemap | Prescribing Information |
Safety Information
This information is for U.S. residents only.
Copyright © 2007 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.
AG4509708/07